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background:  In patients undergoing primary percutaneous coronary intervention (PPCI), morphine delays the pharmacodynamic (PD) 
effects of P2Y12 inhibitors, including prasugrel and ticagrelor. However, to date studies with novel P2Y12 inhibitors have been limited to PD 
assessments. The impact of morphine on pharmacokinetic (PK) profiles remains unexplored and represented the aim of this investigation.
methods:  We conducted a post-hoc analysis of a randomized study evaluating escalating loading doses (LD) of ticagrelor (180, 270 and 
360 mg) in PPCI patients (n=46). PK and PD were assessed before and at 6 time points after LD. PK assessments included plasma levels 
of ticagrelor and its metabolite AR-C124910XX; PD included P2Y12 reaction units (PRU) measured by VerifyNow P2Y12 and platelet 
reactivity index (PRI) measured by VASP.
results:  A total 16/46 (~35%) patients received morphine. In the adjusted analysis, morphine reduced overall PRU levels in the first 2 
hours after LD (p=0.047), while no effect was shown from 4 to 24 hours (p=0.78). Parallel findings were observed with VASP-PRI. The PK 
profile tracked PD findings, showing a delay in peak plasma concentrations of both ticagrelor and AR-C124910XX in patients receiving 
morphine, although overall drug exposure was similar between groups (Figure).
Conclusion:  In PPCI patients, the use of morphine delays the PD effects of ticagrelor which may be attributed to impaired drug absorption, 
as reflected in an altered PK profile in the early hours after LD.
